Here, we analyzed subtype IHC-surrogate marker expression [11] in the CIS lesion(s) of each HR NMIBC patient with available tissue material, comprising luminal (KRT20, GATA3, ERBB2) and basal (KRT5/6, KRT14) markers as well as p53 as a diagnostic marker. Here, ERBB2 is linked to in situ carcinoma.